Description
Book SynopsisThis book, now in an extensively revised second edition, provides a comprehensive summary of the latest knowledge regarding glycosignals and a thorough analysis of their involvement in not only cancers but also other refractory conditions such as chronic inflammatory disorders. Many relevant topics are covered, including the search for novel tumor epitopes related to carbohydrates, the assembly of glycoconjugates, the modulation of signaling pathways by glycosylation, and interactions between complex carbohydrates and their recognition molecules. The role of various research approaches, for example advanced mass spectrometry, high-resolution imaging, and bioinformatics, is closely examined, and the results of novel therapeutic trials targeting glycosignals are discussed. The book will be essential reading for students and young researchers with an interest in glycoscience. In presenting new results and approaches and identifying areas for future research, it will also be of benefit for specialists in the field.
Table of ContentsPart I. Search for novel tumor epitopes related to carbohydrates.- Chapter 1.1. The ganglioside structures: chemistry and biochemistry.- Chapter 1.2. Fucosylated proteins as cancer biomarkers.- Part II. Assembly of glycoconjugates.- Chapter 2.1. Siglec-7 and synthetic sialylpolymer.- Chapter 2.2. Role of Sialyl-Tn antigen in Cancer Metastasis.- Chapter 2.3. Insights into the Role of Chondroitin Sulfate in Cancer.- Part III. Signaling pathways modulated by glycosylation.- Chapter 3.1. Significance of FUT8in pancreatic cancer and others.- Chapter 3.2. Effects of Bullfrog sialic acid-binding lectin in cancer cells.- Part IV. Interaction between carbohydrate and carbohydrate-recognizing molecules.- Chapter 4.1. Opposite functions of mono- and disialylated glycosphingolipids on the membrane of cancer cells.- Chapter 4.2. Tumor progression through interaction of mucins with lectins and subsequent signal transduction.- Part V. Clinical trials targeting glycosignals.- Chapter 5.1. Immunotherapy of Neuroblastoma Targeting GD2 and Beyond.
